124 related articles for article (PubMed ID: 1069548)
1. Randomized trial of Bacillus Calmette-Guérin (percutaneous administration) as surgical adjuvant immunotherapy for patients with stage-II melanoma.
Pinsky CM; Hirshaut Y; Wanebo HJ; Fortner JG; Miké V; Schottenfeld D; Oettgen HF
Ann N Y Acad Sci; 1976; 277(00):187-94. PubMed ID: 1069548
[No Abstract] [Full Text] [Related]
2. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy of human malignant melanoma with irradiated tumor cells, oral Bacillus Calmette-Guérin, and levamisole.
Shibata HR; Jerry LM; Lewis MG; Mansell PW; Capek A; Marquis G
Ann N Y Acad Sci; 1976; 277(00):355-66. PubMed ID: 1069555
[No Abstract] [Full Text] [Related]
4. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B
Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
[TBL] [Abstract][Full Text] [Related]
5. Recurrent malignant melanoma: effect of adjuvant immunotherapy on survival.
McCulloch PB; Dent PB; Blajchman M; Muirhead WM; Price RA
Can Med Assoc J; 1977 Jul; 117(1):33-6. PubMed ID: 861909
[TBL] [Abstract][Full Text] [Related]
6. Bacillus Calmette-Guerin injections for melanoma immunotherapy: potential for a false-positive PET/CT.
Sogge SM; Fotos JS; Tulchinsky M
Clin Nucl Med; 2015 Apr; 40(4):368-9. PubMed ID: 25674877
[TBL] [Abstract][Full Text] [Related]
7. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma.
Tan JK; Ho VC
J Dermatol Surg Oncol; 1993 Nov; 19(11):985-90. PubMed ID: 8245304
[TBL] [Abstract][Full Text] [Related]
8. Long-term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non-treatment in a randomised multicentre study (EORTC Protocol 18781).
Czarnetzki BM; Macher E; Suciu S; Thomas D; Steerenberg PA; Rümke P
Eur J Cancer; 1993; 29A(9):1237-42. PubMed ID: 8343260
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
Sterchi JM; Wells HB; Case LD; Spurr CL; White DR; Richards F; Muss HB; Jackson DV; Stuart JJ; Cooper MR
Cancer; 1985 Feb; 55(4):707-12. PubMed ID: 3967167
[TBL] [Abstract][Full Text] [Related]
10. Pulmonary manifestations in patients with malignant melanoma during BCG immunotherapy. A preliminary report.
Bilgi C; Brown NE; McPherson TA; Lentle B
Chest; 1979 Jun; 75(6):685-7. PubMed ID: 436519
[TBL] [Abstract][Full Text] [Related]
11. Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy.
de la Monte SM; Hutchins GM
Am J Dermatopathol; 1986 Aug; 8(4):331-5. PubMed ID: 3532854
[TBL] [Abstract][Full Text] [Related]
12. Calmette-Guerin bacillus treatment of experimental conjunctival malignant melanoma.
Rutgard J; Peyman GA; Frenkel M; Saks S
Arch Ophthalmol; 1977 Dec; 95(12):2214-7. PubMed ID: 588117
[TBL] [Abstract][Full Text] [Related]
13. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
Lipton A; Harvey HA; Lawrence B; Gottlieb R; Kukrika M; Dixon R; Graham W; Miller S; Heckard R; Schelzel D; White DS
Cancer; 1983 Jan; 51(1):57-60. PubMed ID: 6821809
[TBL] [Abstract][Full Text] [Related]
14. Effect of BCG (Tice strain) on primary sensitization to 2,4-dinitrochlorobenzene and on established delayed hypersensitivity in human malignant melanoma.
Mavligit GM; Gutterman JU; Hersh EM
J Natl Cancer Inst; 1976 Oct; 57(4):749-51. PubMed ID: 1003526
[TBL] [Abstract][Full Text] [Related]
15. Combined immunotherapy in malignant melanoma. Regression of metastatic lesions in two patients concordant in timing with systemic administration of transfer factor and Bacillus Calmette-Guérin.
Spitler LE; Levin AS; Wybran J
Cell Immunol; 1976 Jan; 21(1):1-19. PubMed ID: 764975
[No Abstract] [Full Text] [Related]
16. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
Peter HH; Deutschmann EM; Schultheis W; Deicher H
Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
[TBL] [Abstract][Full Text] [Related]
18. A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma.
O'Connor TP; Labandter HP; Hiles RW; Bodenham DC
Br J Plast Surg; 1978 Oct; 31(4):317-22. PubMed ID: 361132
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
El-Domeiri AA; Das Gupta TK; Trippon M; Simo C; Sabet TY; Crispen R
Surg Gynecol Obstet; 1978 Feb; 146(2):230-2. PubMed ID: 622668
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy: an overview.
Morton DL
Semin Oncol; 1974 Dec; 1(4):297-310. PubMed ID: 4620437
[No Abstract] [Full Text] [Related]
[Next] [New Search]
